TWI870228B - 吡咯啶化合物的結晶 - Google Patents

吡咯啶化合物的結晶 Download PDF

Info

Publication number
TWI870228B
TWI870228B TW113104509A TW113104509A TWI870228B TW I870228 B TWI870228 B TW I870228B TW 113104509 A TW113104509 A TW 113104509A TW 113104509 A TW113104509 A TW 113104509A TW I870228 B TWI870228 B TW I870228B
Authority
TW
Taiwan
Prior art keywords
crystals
pyrrolidine
crystal
phosphoric acid
patent application
Prior art date
Application number
TW113104509A
Other languages
English (en)
Chinese (zh)
Other versions
TW202421621A (zh
Inventor
子
長田裕臣
吉田紘
Original Assignee
日商田邊三菱製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商田邊三菱製藥股份有限公司 filed Critical 日商田邊三菱製藥股份有限公司
Publication of TW202421621A publication Critical patent/TW202421621A/zh
Application granted granted Critical
Publication of TWI870228B publication Critical patent/TWI870228B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • AIDS & HIV (AREA)
  • Ophthalmology & Optometry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW113104509A 2018-12-28 2019-12-27 吡咯啶化合物的結晶 TWI870228B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018-247437 2018-12-28
JP2018247437 2018-12-28

Publications (2)

Publication Number Publication Date
TW202421621A TW202421621A (zh) 2024-06-01
TWI870228B true TWI870228B (zh) 2025-01-11

Family

ID=71127176

Family Applications (2)

Application Number Title Priority Date Filing Date
TW113104509A TWI870228B (zh) 2018-12-28 2019-12-27 吡咯啶化合物的結晶
TW108148109A TWI834791B (zh) 2018-12-28 2019-12-27 吡咯啶化合物的結晶

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW108148109A TWI834791B (zh) 2018-12-28 2019-12-27 吡咯啶化合物的結晶

Country Status (8)

Country Link
US (2) US12077524B2 (https=)
EP (3) EP4603143A3 (https=)
JP (3) JP6977185B2 (https=)
CN (3) CN120081826A (https=)
ES (1) ES2991904T3 (https=)
MA (1) MA54619A (https=)
TW (2) TWI870228B (https=)
WO (1) WO2020138481A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI882128B (zh) 2020-06-10 2025-05-01 日商田邊三菱製藥股份有限公司 紫質症之預防或治療劑
MX2022015804A (es) 2020-06-10 2023-04-05 Mitsubishi Tanabe Pharma Corp Agente profilactico o terapeutico para porfiria.
KR20230016008A (ko) 2020-06-10 2023-01-31 미쓰비시 타나베 파마 코퍼레이션 광선성 피부질환의 예방 또는 치료제
US20240228473A1 (en) * 2021-05-06 2024-07-11 Lg Chem, Ltd. Crystalline form v of melanocortin receptor agonist compound, and method for preparing same
US20240239783A1 (en) * 2021-05-06 2024-07-18 Lg Chem, Ltd. Crystal form vii of melanocortin receptor agonist compound and method for preparing same
AU2022271120A1 (en) * 2021-05-07 2023-11-09 Lg Chem, Ltd. Crystal form iv of organic acid salts of melanocortin receptor agonist compound, and preparation method thereof
CN117242063A (zh) * 2021-05-07 2023-12-15 株式会社Lg化学 黑皮质素受体激动剂化合物与香兰素的共晶及其制备方法
BR112023022334A2 (pt) * 2021-05-07 2023-12-26 Lg Chemical Ltd Formas cristalinas de sulfato do composto agonista do receptor de melanocortina, seus métodos de preparação, seus usos, e composições farmacêuticas compreendendo as mesmas
WO2023145959A1 (ja) 2022-01-31 2023-08-03 田辺三菱製薬株式会社 メラノコルチン１受容体アゴニストの新規用途
CN119654150A (zh) * 2022-08-03 2025-03-18 田边三菱制药株式会社 含有1-｛2-[（3s,4r）-1-｛[（3r,4r）-1-环戊基-3-氟-4-（4-甲氧基苯基）吡咯烷-3-基]羰基｝-4-（甲氧基甲基）吡咯烷-3-基]-5-（三氟甲基）苯基｝哌啶-4-甲酸或其药学上可接受的盐或者共晶的药物组合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015182723A1 (ja) * 2014-05-29 2015-12-03 田辺三菱製薬株式会社 新規ピロリジン化合物およびメラノコルチン受容体作動薬としての用途
JP2017105765A (ja) * 2015-11-27 2017-06-15 田辺三菱製薬株式会社 医薬組成物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1790637B1 (en) * 2004-09-13 2014-01-29 Ono Pharmaceutical Co., Ltd. Derivatives of N-4-piperidyl urea and medicaments containing them as active ingredient
EP1951286A4 (en) * 2005-10-07 2009-11-04 Waratah Pharmaceuticals Inc COMBINED USE OF INHIBITORS OF DPP-IV AND GASTRIN COMPOUNDS

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015182723A1 (ja) * 2014-05-29 2015-12-03 田辺三菱製薬株式会社 新規ピロリジン化合物およびメラノコルチン受容体作動薬としての用途
JP2017105765A (ja) * 2015-11-27 2017-06-15 田辺三菱製薬株式会社 医薬組成物

Also Published As

Publication number Publication date
EP3903785B1 (en) 2024-10-02
JP2022024034A (ja) 2022-02-08
JP7652682B2 (ja) 2025-03-27
CN113226314B (zh) 2025-03-18
US20220073497A1 (en) 2022-03-10
EP4434582A2 (en) 2024-09-25
WO2020138481A1 (ja) 2020-07-02
EP4434582A3 (en) 2024-12-18
EP4603143A2 (en) 2025-08-20
TW202517631A (zh) 2025-05-01
CN120081826A (zh) 2025-06-03
TW202039464A (zh) 2020-11-01
JP2025085744A (ja) 2025-06-05
CN113226314A (zh) 2021-08-06
JPWO2020138481A1 (ja) 2021-09-27
US12077524B2 (en) 2024-09-03
EP4603143A3 (en) 2025-11-05
TW202421621A (zh) 2024-06-01
CN120081827A (zh) 2025-06-03
JP6977185B2 (ja) 2021-12-08
MA54619A (fr) 2021-11-03
TWI834791B (zh) 2024-03-11
EP3903785A1 (en) 2021-11-03
US20250002474A1 (en) 2025-01-02
ES2991904T3 (es) 2024-12-05
EP3903785A4 (en) 2022-08-10

Similar Documents

Publication Publication Date Title
TWI870228B (zh) 吡咯啶化合物的結晶
CN114728899B (zh) 新型三苯基化合物盐
US10023577B2 (en) Crystalline form of JAK kinase inhibitor bisulfate and a preparation method thereof
JP7153030B2 (ja) オピオイド受容体（ｍｏｒ）アゴニスト塩、そのフマレート塩ｉ結晶形態、およびその製造方法
EP3205653B1 (en) Crystal form of bisulfate of jak inhibitor and preparation method therefor
TW201718516A (zh) 組蛋白去乙醯酶抑制劑之晶形
US9169257B2 (en) Crystal forms of adefovir dipivoxil and processes for preparing the same
TWI919623B (zh) 吡咯啶化合物的結晶
WO2023061372A1 (zh) 占诺美林衍生物的苹果酸盐、a晶型及其制备方法和用途
HK40130190A (en) Crystal of pyrrolidine compound
US20120059034A1 (en) Novel crystalline hydrate, amorphous and polymorphic forms of dihydro-benzoxazole-6-yl-acetamide derivative and processes for their preparation
CN104768927A (zh) (3s,3s’)-4,4’-二硫烷二基双(3-氨基丁烷-1-磺酸)合l-赖氨酸的新的结晶相
JP2025510061A (ja) 縮合三環式誘導体又はその薬学的に許容される塩の結晶
CN106518952A (zh) 醋酸曲安奈德晶型b、其制备方法、包含所述晶型b的药物组合物和用途
HK40007656A (zh) 地匹福林盐酸盐的稳定型晶体及其结晶化方法
WO2013058361A1 (ja) アンドロゲン受容体拮抗化合物の結晶